SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) previously announced that a
proposal was approved at its Special Meeting of Stockholders, held
September 7, 2017, authorizing its Board of Directors to amend the
Company's certificate of incorporation to effect a reverse stock split
of the Company's issued and outstanding shares of common stock at a
ratio not less than 1-for-8 and not greater than 1-for-12, with the
exact ratio to be set within that range by Tandem's Board of Directors.
The number of authorized shares of common stock would remain at 100
million shares. Tandem's Board of Directors had previously directed that
the proposal be submitted to the shareholders for approval and has
subsequently approved the reverse stock split at a ratio of 1-for-10.
The reverse stock split will take effect at 4:00 pm ET on October 9,
2017. Beginning with the opening of trading on October 10, 2017, the
Company's common stock will trade on the NASDAQ Global Market on a
reverse stock split-adjusted basis.
"The implementation of this reverse stock split will provide us with
flexibility in our capital structure to pursue financing alternatives in
support of our business plan and to bring new innovations to people with
diabetes," said Kim Blickenstaff, President and CEO of Tandem Diabetes
Care. "With our team of dedicated employees, differentiated insulin
pumps, and meaningful history of growth and operational progress, we
remain keenly focused on building long-term shareholder value."
Upon the effectiveness of the reverse stock split, every ten shares of
the Company's issued and outstanding common stock will be automatically
reclassified and converted into one issued and outstanding share of
common stock, par value $0.001 per share. As a result of the reverse
split, there will be approximately 5.5 million shares of common stock
issued and outstanding. The shares of common stock will trade under a
new CUSIP number, 875372203, effective October 10, 2017. The Company's
trading symbol will remain "TNDM." All options, warrants, and
convertible securities of the Company outstanding immediately prior to
the reverse stock split will be adjusted.
No fractional shares of common stock will be issued as a result of the
reverse stock split. Stockholders who would otherwise be entitled to
receive a fractional share as a result of the reverse stock split will
instead receive one whole share of common stock.
The Company has chosen its transfer agent, American Stock Transfer &
Trust Company, LLC ("AST"), to act as exchange agent for the reverse
stock split. Stockholders owning shares via a bank, broker or other
nominee will have their positions automatically adjusted to reflect the
reverse stock split, and will not be required to take further action in
connection with the reverse stock split, subject to brokers' particular
processes. For those stockholders holding physical stock certificates,
AST will send instructions for exchanging those certificates for shares
held in book-entry form representing the post-split number of shares.
AST can be reached at (800) 937-5449.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem manufactures and sells the t:slim
X2™ Insulin Pump, the only pump capable of remote feature updates using
a personal computer, now available with Dexcom G5® Mobile continuous
glucose monitoring (CGM) integration, and the t:flex® Insulin Pump, the
first pump designed for people with greater insulin requirements. Tandem
is based in San Diego, California.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2
is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 is a registered
trademark of Dexcom, Inc.
Forward Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
include statements regarding the reverse stock split and building
long-term shareholder value. The Company's actual results, and the
timing of events, could differ materially from those indicated in these
forward-looking statements due to numerous risks and uncertainties,
including the Company's ability to satisfy conditions related to the
implementation of the reverse split and the Company's ability to achieve
its business plans and bring new innovations to people with diabetes. In
addition, the Company's results may be impacted by the other risks
identified in the Company's most recent Annual Report on Form 10-K and
Quarterly report on Form 10-Q, and other documents that the Company
files with the Securities and Exchange Commission. Investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Unless
otherwise required by applicable law or the rules of the NASDAQ Stock
Market, the Company undertakes no obligation to update or review any
forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171009005339/en/
Tandem Diabetes Care, Inc.
Media Contact:
Steve
Sabicer, 714-907-6264
ssabicer@thesabicergroup.com
or
Investor
Contact:
Susan Morrison, 858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care, Inc.
News Provided by Acquire Media
